+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

DNA ploidy and MYC DNA amplification in ovarian carcinomas. Correlation with p53 and bcl-2 expression, proliferative activity and prognosis

DNA ploidy and MYC DNA amplification in ovarian carcinomas. Correlation with p53 and bcl-2 expression, proliferative activity and prognosis

Virchows Archiv 429(4-5): 221-227

There is increasing evidence that DNA ploidy is a prognostic factor in ovarian carcinomas, but it is uncertain whether MYC DNA amplification is an epiphenomenon of DNA nondiploidy or a distinct biological change with an impact on the clinical course of the disease. To clarify these issues we analysed DNA ploidy by flow and image cytometry and MYC copy number by polymerase chain reaction in archival material from ovarian carcinomas with known follow up. The results were compared with proliferative activity (Ki67 index) and p53 and bcl-2 expression. DNA cytometry revealed nondiploidy in 84 of 144 cases (58.3%). Nondiploidy was statistically significantly correlated with histological tumour type, histological grade, Ki67 index > 10%, FIGO stage, presence of residual tumour after debulking surgery and adverse postoperative outcome. Furthermore, DNA nondiploidy was associated with p53 accumulation. We found that 84.9% of the p53-positive cases were nondiploid. This points to the paramount importance of wild type p53 for the maintenance of genome integrity in this tumour type. MYC DNA amplification was seen in 33.8% (26/77 cases) of ovarian carcinoma. There was no correlation between MYC DNA amplification and histological tumour type, histological grade, FIGO stage, DNA ploidy, proliferative activity or prognosis. However, when p53 and bcl-2 expression was taken into account, a statistically significant correlation between gene alteration or expression patterns and histological tumour type was revealed. The group of mucinous carcinomas demonstrated both MYC DNA amplification and strong bcl-2 expression in 50% and contained the largest fraction of cases without aberration (37.5%). Endometrioid carcinomas were characterized by strong bcl-2 expression in 85%, whereas serous and undifferentiated carcinomas predominantly exhibited p53 alterations, frequently accompanied by bcl-2 overexpression or MYC DNA amplification. Thus, in interaction with other genes MYC DNA amplification may play a role in the determination of the varying differentiation patterns of ovarian carcinomas.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 008416646

Download citation: RISBibTeXText

PMID: 8972757

Related references

C-myc and p53 Expression DNA-ploidy and proliferative activity in non-mucinous ovarian carcinomas. Pathology Research & Practice 190(3): 270, 1994

Correlation between nucleolar organizer regions ploidy status and proliferative activity in primary breast carcinomas. International Journal of Biological Markers 6(1): 69, 1991

Expression of PPAR gamma, Ki-67 and DNA ploidy in urothelial carcinomas and correlation with prognosis of patients.. 2007

Ploidy, proliferative activity, p53 and bcl-2 expression in bronchopulmonary carcinoids: Relationship with prognosis. Pathology Research & Practice 195(7): 467-474, 1999

Alterations of the 16q22.1 and 16q24.3 chromosomal loci in sporadic invasive breast carcinomas: correlation with proliferative activity, ploidy and hormonal status of the tumors. Anticancer Research 21(2a): 991-999, 2001

Dna ploidy andMycdna amplification in ovarian carcinomas. Virchows Archiv 429(4-5): 221-227, 1996

DNA content and proliferative activity in ovarian small cell carcinomas of the hypercalcemic type. Implications for diagnosis, prognosis, and histogenesis. American Journal of Clinical Pathology 98(6): 579-586, 1992

DNA ploidy in breast carcinomas Correlation with HER-2/neu amplification and overexpression. Clinical Research 42(1): 56A, 1994

Correlation Between Immunohistochemical Biomarkers Expression and Prognosis of Ovarian Carcinomas in Tunisian Patients. World Journal of Oncology 1(3): 118-128, 2010

The relationship between C-erbB-2 expression with cell proliferative activity and prognosis of nasopharyngeal carcinomas. Hunan Yi Ke Da Xue Xue Bao 23(3): 235-238, 2000

Association of p53 expression with proliferative activity and poor-prognosis in patients with squamous-cell lung carcinomas. International Journal of Oncology 5(3): 533-538, 1994

High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas: relation to E-cadherin alterations, proliferative activity, and ploidy of the tumors. Cancer 94(9): 2454-2465, 2002

Cytophotometric measurements of nuclear DNA content of bronchogenic carcinomas. II. The DNA ploidy and proliferative activity of bronchogenic carcinomas. Taiwan Yi Xue Hui Za Zhi. Journal of the Formosan Medical Association 84(7): 785-792, 1985

Ovarian cancer prognosis and expression of receptors to sex hormones and proliferative activity of tumor cells. Arkhiv Patologii 68(2): 10-13, 2006

Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma. American Journal of Pathology 136(5): 1043-1052, 1990